Miami Cancer Institute Breast Cancer Genetics Update

Miami Cancer Institute Breast Cancer Genetics Update is organized by Baptist Health South Florida.

Course opens: 11/01/2023
Course expires: 10/31/2026

Description:
Miami Cancer Institute’s Breast Cancer Genetics Update provides a comprehensive overview of breast cancer treatment and genomic testing in patients with BRCA1/2 +/- PALB2, HR+/HER2- breast cancer, HER2+ disease, triple-negative breast cancer and populations with ESR1 mutations.

Deaths per year from breast cancer are declining because of advances in HER2+ disease. The incorporation of genomic assays has allowed us to better tailor our treatment recommendations for patients with HR+/HER2- breast cancer.  A better understanding of molecular mechanisms underlying pathogenesis of HER2+ disease has generated targeted therapy options to combat this poor prognosis. This course provides learners with an overview of the recent advances in available treatment for HR+/HER2- early breast cancer patients and in advanced disease populations with ESR1 mutation.

This course also addresses current and emerging therapeutic options for triple-negative breast cancer. The role of adjuvant immunotherapy in early-stage disease is discussed, as well as the role of additional therapy in those patients with residual disease. The course assesses the chemotherapy backbone of treatment planning in triple-negative patients.

This course concludes by delving further into genetic testing. The role of a cancer genetic counselor becomes essential when considering universal testing for the most actionable genes (BRCA1/2 +/- PALB2) and guiding treatment plans when multi-gene panels identify genes of uncertain significance.

Topics include:
• Breast Cancer Genomic Testing – Clinical Applications
• Challenges in HER2+ Breast Cancer
• Current and Emerging Therapeutic Options for Triple-Negative Breast Cancer: Immunotherapy and Beyond
• Universal Testing for Breast Cancer Predisposition

Learning Objectives:
• Incorporate genomic assays to better tailor treatment recommendations for patients with HR+/HER2- breast cancer.
• Examine the benefits of chemotherapy over ovarian function suppression in premenopausal women.
• Utilize adjuvant therapies for high-risk patients with HR+/HER2- early breast cancer.
• Discuss how ESR1 mutation testing is now actionable in advanced disease populations.
• Define advanced triple-negative breast cancer (TNBC) standard of care treatment vs. early TNBC standard of care and explain investigational agents/regimens. 
• Recognize molecular mechanisms underlying pathogenesis of HER2+ disease and develop targeted therapy to combat poor prognosis.
• Explain genetic testing criteria and examine the performance characteristics of testing criteria (sensitivity, specificity, PPV, NPV).
• Recognize the implications of including moderate penetrance genes in broad genetic testing.